Rose Weldon News Today

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are...

CAMBRIDGE, Mass., April 24, 2024 -- Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1...

Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies Follows ongoing clinical study of...

CAMBRIDGE, Mass., June 01, 2024 -- Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in...

CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology") a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced

CAMBRIDGE, Mass., Dec. 18, 2023 --  Cullinan Oncology, Inc. a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer,...

CAMBRIDGE, Mass., Dec. 14, 2023 -- Cullinan Oncology, Inc. , a bi...

Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024

Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed...